Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Travere Therapeutics, Inc. (TVTX : NSDQ)

• Company Description    Travere Therapeutics Inc. is a biopharmaceutical company. It engages to identify, develop and deliver life-changing therapies. Travere Therapeutics Inc., formerly known as Retrophin Inc., is based in SAN DIEGO. Number of Employees: 310

• Price / Volume Information    Yesterday's Closing Price: $24.60 Daily Weekly Monthly 20 Day Moving Average: 912,684 shares Shares Outstanding: 63.51 (millions) Market Capitalization: $1,562.45 (millions) Beta: 0.72 52 Week High: $31.65 52 Week Low: $12.75 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -12.89% -1.88% 12 Week -9.43% -0.42% Year To Date -20.75% -3.17%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 3611 VALLEY CENTRE DR SUITE 300 - SAN DIEGO,CA 92130 USA ph: 888-969-7879 fax: 302-645-1280 ir@travere.com https://travere.com

• General Corporate Information    Officers Eric M. Dube - Chief Executive Officer Laura Clague - Chief Financial Officer Sandra Calvin - Vice President; Corporate Controller and Chief Acc Stephen Aselage - Director Roy D. Baynes - Director Peer Information Travere Therapeutics, Inc. (CORR.) Travere Therapeutics, Inc. (RSPI) Travere Therapeutics, Inc. (CGXP) Travere Therapeutics, Inc. (BGEN) Travere Therapeutics, Inc. (GTBP) Travere Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 89422G107 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/04/22 Share - Related Items Shares Outstanding: 63.51 Most Recent Split Date: (:1) Beta: 0.72 Market Capitalization: $1,562.45 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.89 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-3.71 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/04/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 7.51 Price/Cash Flow: - Price / Sales: 6.84 EPS Growth vs. Year Ago Period: -25.00% vs. Previous Quarter: -42.86% Sales Growth vs. Year Ago Period: 2.28% vs. Previous Quarter: -15.31% ROE 03/31/22 - -70.33 12/31/21 - -55.22 09/30/21 - -82.45 ROA 03/31/22 - -25.86 12/31/21 - -23.52 09/30/21 - -34.58 Current Ratio 03/31/22 - 5.28 12/31/21 - 4.70 09/30/21 - 5.12 Quick Ratio 03/31/22 - 5.23 12/31/21 - 4.64 09/30/21 - 5.06 Operating Margin 03/31/22 - -88.46 12/31/21 - -79.16 09/30/21 - -113.07 Net Margin 03/31/22 - -88.46 12/31/21 - -79.16 09/30/21 - -113.07 Pre-Tax Margin 03/31/22 - -88.40 12/31/21 - -78.99 09/30/21 - -113.10 Book Value 03/31/22 - 3.28 12/31/21 - 4.93 09/30/21 - 5.02 Inventory Turnover 03/31/22 - 1.04 12/31/21 - 0.95 09/30/21 - 0.97 Debt-to-Equity 03/31/22 - 1.80 12/31/21 - 0.75 09/30/21 - 0.73 Debt-to-Capital 03/31/22 - 64.27 12/31/21 - 42.86 09/30/21 - 42.12

Powered by Zacks Investment Research ©